AQR Capital Management
PRVB

AQR Capital Management’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

AQR Capital Management’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-13,864
Closed -$62K – 2316
2022
Q3 		$62K Buy
+13,864
New +$63.2K ﹤0.01% 2137
2021
Q1 		– Sell
-19,446
Closed -$329K – 2297
2020
Q4 		$329K Sell
19,446
-3,926
-17% -$58.8K ﹤0.01% 1938
2020
Q3 		$300K Buy
+23,372
New +$295K ﹤0.01% 1914

Other funds holding PRVB

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

AQR Capital Management's PRVB Position: Q4 2022 in Review

AQR Capital Management sold out of Provention Bio, Inc. Common Stock (PRVB) in Q4 2022, closing a stake of 13,864 shares — an estimated $62K sold.

AQR Capital Management first reported a position in PRVB in Q3 2020 and held it in 3 quarters. The position peaked at $329K in Q4 2020. 133 funds tracked by Wall St. Rank hold PRVB as of Q4 2022.

  • AQR Capital Management reported no remaining Provention Bio, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • AQR Capital Management sold 13,864 Provention Bio, Inc. Common Stock shares in Q4 2022, an estimated $62K.
  • AQR Capital Management first reported a position in Provention Bio, Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • AQR Capital Management's Provention Bio, Inc. Common Stock position peaked at $329K in Q4 2020.
  • 133 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q4 2022.

Based on AQR Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.